TYK Medicines' (HKG:2410) asandeutertinib mesylate tablets obtained conditional approval for marketing from China's National Medical Products Administration, according to a Thursday bourse filing.
Shares of the pharmaceutical company were down nearly 6% in Friday afternoon trading.
The approval is for the indication of the first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.